Compare WSBF & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSBF | CMPS |
|---|---|---|
| Founded | 1921 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.1M | 611.6M |
| IPO Year | N/A | 2020 |
| Metric | WSBF | CMPS |
|---|---|---|
| Price | $16.48 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.43 |
| AVG Volume (30 Days) | 46.1K | ★ 1.3M |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 87.32 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $137,060,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.41 | ★ N/A |
| Revenue Growth | ★ 2.87 | N/A |
| 52 Week Low | $11.61 | $2.25 |
| 52 Week High | $17.26 | $7.15 |
| Indicator | WSBF | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 60.30 |
| Support Level | $16.26 | $6.08 |
| Resistance Level | $16.67 | $7.15 |
| Average True Range (ATR) | 0.35 | 0.39 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 35.77 | 62.62 |
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.